Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Parker

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Genetic Epidemiology|June 4, 2009
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studiesRobert J MacInnis, Antonis C Antoniou, Rosalind A Eeles, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Genetic Epidemiology|June 4, 2009
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studiesRobert J MacInnis, Antonis C Antoniou, Rosalind A Eeles, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Pageof 6